病毒疗法 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "病毒疗法" in Chinese language version.

refsWebsite

Global rank Chinese rank

21web.archive.org

1^st place

21nih.gov

4^th place

5^th place

18doi.org

2^nd place

23^rd place

4fda.gov

447^th place

581^st place

4worldcat.org

5^th place

12^th place

4europa.eu

68^th place

209^th place

2nature.com

234^th place

227^th place

2nytimes.com

7^th place

31^st place

2reuters.com

49^th place

81^st place

1uk-cpi.com

low place

1archive.org

6^th place

4^th place

1mayoclinic.org

1,610^th place

2,275^th place

1vaccines.gov

low place

1zva.gov.lv

low place

1lsm.lv

3,067^th place

low place

archive.org

Moore, AE. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer. May 1949, 2 (3): 525–34. PMID 18131412. doi:10.1002/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O.

doi.org

Kelly, E; Russell, SJ. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy. April 2007, 15 (4): 651–9 [2020-08-30]. PMID 17299401. doi:10.1038/sj.mt.6300108 . （原始内容存档于2016-12-03）.
Moore, AE. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer. May 1949, 2 (3): 525–34. PMID 18131412. doi:10.1002/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O.
Huebner, RJ; Rowe, WP; Schatten, WE; Smith, RR; Thomas, LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. Nov–Dec 1956, 9 (6): 1211–8. PMID 13383455. doi:10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7.
Fukuhara, H; Ino, Y; Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn.. Cancer Science. 2016-08-03, 107 (10): 1373–1379. PMC 5084676 . PMID 27486853. doi:10.1111/cas.13027.
Bilsland, AE; Spiliopoulou, P; Evans, TR. Virotherapy: cancer gene therapy at last?. F1000Research. 2016, 5: 2105. PMC 5007754 . PMID 27635234. doi:10.12688/f1000research.8211.1.
Fukuhara, H; Ino, Y; Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn.. Cancer Science. 2016-08-03, 107 (10): 1373–1379. PMC 5084676 . PMID 27486853. doi:10.1111/cas.13027.
Bilsland, AE; Spiliopoulou, P; Evans, TR. Virotherapy: cancer gene therapy at last?. F1000Research. 2016, 5: 2105. PMC 5007754 . PMID 27635234. doi:10.12688/f1000research.8211.1.
Cross, Deanna; Burmester, James K. Gene Therapy for Cancer Treatment: Past, Present and Future. Clinical Medicine and Research. 2006, 4 (3): 218–227. ISSN 1539-4182. PMC 1570487 . PMID 16988102. doi:10.3121/cmr.4.3.218.
Bessis, N.; GarciaCozar, F. J.; Boissier, M.-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004, 11 (1): S10–S17. ISSN 1476-5462. PMID 15454952. doi:10.1038/sj.gt.3302364  （英语）.
Bessis, N.; GarciaCozar, F. J.; Boissier, M.-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004, 11 (1): S10–S17. ISSN 1476-5462. PMID 15454952. doi:10.1038/sj.gt.3302364  （英语）.
Zhou, Ru; Caspi, Rachel R. Ocular immune privilege. F1000 Biology Reports. 2010-01-18, 2. ISSN 1757-594X. PMC 2948372 . PMID 20948803. doi:10.3410/B2-3.
Hanley, KA. The double-edged sword: How evolution can make or break a live-attenuated virus vaccine.. Evolution. December 2011, 4 (4): 635–643. PMC 3314307 . PMID 22468165. doi:10.1007/s12052-011-0365-y.
Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.. Oncolytic Virotherapy. 2017, 6: 11–18. PMC 5308590 . PMID 28224120. doi:10.2147/OV.S100072.
Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.. Oncolytic Virotherapy. 2017, 6: 11–18. PMC 5308590 . PMID 28224120. doi:10.2147/OV.S100072.
Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.. Oncolytic Virotherapy. 2017, 6: 11–18. PMC 5308590 . PMID 28224120. doi:10.2147/OV.S100072.
Keen, E. C. Beyond phage therapy: Virotherapy of protozoal diseases. Future Microbiology. 2013, 8 (7): 821–823. PMID 23841627. doi:10.2217/FMB.13.48.
Hyman, P.; Atterbury, R.; Barrow, P. Fleas and smaller fleas: Virotherapy for parasite infections. Trends in Microbiology. 2013, 21 (5): 215–220. PMID 23540830. doi:10.1016/j.tim.2013.02.006.
Keen, Eric C. Beyond phage therapy: virotherapy of protozoal diseases. Future Microbiology. July 2013, 8 (7): 821–823. PMID 23841627. doi:10.2217/fmb.13.48.

europa.eu

ema.europa.eu

Glybera: EPAR - Summary for the public (PDF). European Medicines Agency. [2019-11-25]. （原始内容存档 (PDF)于2020-07-20）.
Glybera: EPAR - Summary for the public (PDF). European Medicines Agency. [2019-11-25]. （原始内容存档 (PDF)于2020-07-20）.
Luxturna : EPAR - Medicine overview (PDF). European Medicines Agency. [2019-11-25]. （原始内容存档 (PDF)于2019-08-31）.

ec.europa.eu

Feasibility study for registration of medicine RIGVIR with the European Medicine Agency. European Commission. 2016-01-08 [2016-11-02]. （原始内容存档于2016-11-02）. However, further use and commercialisation in the EU is prevented as EU regulations require cancer medicines to be registered centrally through the European Medicine Agency (EMA). National registrations are not considered.

fda.gov

Imlygic label (PDF). FDA. October 2015 [2016-10-16]. （原始内容存档 (PDF)于2016-10-23）. For label updates see FDA index page for BLA 125518 （页面存档备份，存于互联网档案馆）
FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. U.S. Food & Drug Administration. 2017-12-18 [2019-11-25]. （原始内容存档于2019-11-24）.
Package Insert - LUXTURNA (voretigene neparvovec-rzyl) (PDF). U.S. Food & Drug Administration. [2019-11-25]. （原始内容存档 (PDF)于2018-01-26）.
Package Insert - ZOLGENSMA (PDF). U.S. Food & Drug Administration. [2019-11-25]. （原始内容存档于2019-11-19）.

lsm.lv

eng.lsm.lv

Rigvir cancer treatment at center of fresh controversy. [2020-08-30]. （原始内容存档于2019-03-27）.

mayoclinic.org

Gene therapy - Mayo Clinic. www.mayoclinic.org. [2019-12-05]. （原始内容存档于2019-12-05）.

nature.com

Kelly, E; Russell, SJ. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy. April 2007, 15 (4): 651–9 [2020-08-30]. PMID 17299401. doi:10.1038/sj.mt.6300108 . （原始内容存档于2016-12-03）.
Clinical virotherapy: four historically significant clinical trials. [2020-08-30]. （原始内容存档于2016-12-04）.

nih.gov

ncbi.nlm.nih.gov

Kelly, E; Russell, SJ. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy. April 2007, 15 (4): 651–9 [2020-08-30]. PMID 17299401. doi:10.1038/sj.mt.6300108 . （原始内容存档于2016-12-03）.
Moore, AE. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer. May 1949, 2 (3): 525–34. PMID 18131412. doi:10.1002/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O.
Huebner, RJ; Rowe, WP; Schatten, WE; Smith, RR; Thomas, LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. Nov–Dec 1956, 9 (6): 1211–8. PMID 13383455. doi:10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7.
Fukuhara, H; Ino, Y; Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn.. Cancer Science. 2016-08-03, 107 (10): 1373–1379. PMC 5084676 . PMID 27486853. doi:10.1111/cas.13027.
Bilsland, AE; Spiliopoulou, P; Evans, TR. Virotherapy: cancer gene therapy at last?. F1000Research. 2016, 5: 2105. PMC 5007754 . PMID 27635234. doi:10.12688/f1000research.8211.1.
Fukuhara, H; Ino, Y; Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn.. Cancer Science. 2016-08-03, 107 (10): 1373–1379. PMC 5084676 . PMID 27486853. doi:10.1111/cas.13027.
Bilsland, AE; Spiliopoulou, P; Evans, TR. Virotherapy: cancer gene therapy at last?. F1000Research. 2016, 5: 2105. PMC 5007754 . PMID 27635234. doi:10.12688/f1000research.8211.1.
Cross, Deanna; Burmester, James K. Gene Therapy for Cancer Treatment: Past, Present and Future. Clinical Medicine and Research. 2006, 4 (3): 218–227. ISSN 1539-4182. PMC 1570487 . PMID 16988102. doi:10.3121/cmr.4.3.218.
Bessis, N.; GarciaCozar, F. J.; Boissier, M.-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004, 11 (1): S10–S17. ISSN 1476-5462. PMID 15454952. doi:10.1038/sj.gt.3302364  （英语）.
Bessis, N.; GarciaCozar, F. J.; Boissier, M.-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004, 11 (1): S10–S17. ISSN 1476-5462. PMID 15454952. doi:10.1038/sj.gt.3302364  （英语）.
Zhou, Ru; Caspi, Rachel R. Ocular immune privilege. F1000 Biology Reports. 2010-01-18, 2. ISSN 1757-594X. PMC 2948372 . PMID 20948803. doi:10.3410/B2-3.
Hanley, KA. The double-edged sword: How evolution can make or break a live-attenuated virus vaccine.. Evolution. December 2011, 4 (4): 635–643. PMC 3314307 . PMID 22468165. doi:10.1007/s12052-011-0365-y.
Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.. Oncolytic Virotherapy. 2017, 6: 11–18. PMC 5308590 . PMID 28224120. doi:10.2147/OV.S100072.
Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.. Oncolytic Virotherapy. 2017, 6: 11–18. PMC 5308590 . PMID 28224120. doi:10.2147/OV.S100072.
Babiker, HM; Riaz, IB; Husnain, M; Borad, MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.. Oncolytic Virotherapy. 2017, 6: 11–18. PMC 5308590 . PMID 28224120. doi:10.2147/OV.S100072.
Keen, E. C. Beyond phage therapy: Virotherapy of protozoal diseases. Future Microbiology. 2013, 8 (7): 821–823. PMID 23841627. doi:10.2217/FMB.13.48.
Hyman, P.; Atterbury, R.; Barrow, P. Fleas and smaller fleas: Virotherapy for parasite infections. Trends in Microbiology. 2013, 21 (5): 215–220. PMID 23540830. doi:10.1016/j.tim.2013.02.006.
Keen, Eric C. Beyond phage therapy: virotherapy of protozoal diseases. Future Microbiology. July 2013, 8 (7): 821–823. PMID 23841627. doi:10.2217/fmb.13.48.

ghr.nlm.nih.gov

How does gene therapy work?. U.S. National Library of Medicine: Genetics Home Reference. [2019-12-05]. （原始内容存档于2019-12-05）（英语）.
How does gene therapy work?. U.S. National Library of Medicine: Genetics Home Reference. [2019-12-05]. （原始内容存档于2019-12-05）（英语）.
How does gene therapy work?. U.S. National Library of Medicine: Genetics Home Reference. [2019-12-05]. （原始内容存档于2019-12-05）（英语）.

nytimes.com

Amgen to Buy BioVex, Maker of Cancer Drugs. Bloomberg News via The New York Times. 2011-01-24 [2020-08-30]. （原始内容存档于2020-05-15）.
Sepkowitz, Kent. West Nile Made Its U.S. Debut in the 1950s, in a Doctor's Syringe. The New York Times. 2009-08-24: D5 [2020-08-30]. （原始内容存档于2020-08-23）.

reuters.com

Erman, Michael. Novartis says it knew of Zolgensma data problems before U.S. approval. Reuters. 2019-08-07 [2019-11-26]. （原始内容存档于2019-11-17）（英语）.
Erman, Michael. Novartis says it knew of Zolgensma data problems before U.S. approval. Reuters. 2019-08-07 [2019-11-26]. （原始内容存档于2019-11-17）（英语）.

uk-cpi.com

Stephen, Sam. How Science Is Using Viruses To Make You Better - CPI. CPI. [2018-10-31]. （原始内容存档于2018-10-31）（英语）.

vaccines.gov

Services, U.S. Department of Health and Human. Vaccines.gov. www.vaccines.gov. [2020-08-30]. （原始内容存档于2017-07-29）（美国英语）.

web.archive.org

Stephen, Sam. How Science Is Using Viruses To Make You Better - CPI. CPI. [2018-10-31]. （原始内容存档于2018-10-31）（英语）.
Kelly, E; Russell, SJ. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy. April 2007, 15 (4): 651–9 [2020-08-30]. PMID 17299401. doi:10.1038/sj.mt.6300108 . （原始内容存档于2016-12-03）.
Clinical virotherapy: four historically significant clinical trials. [2020-08-30]. （原始内容存档于2016-12-04）.
Imlygic label (PDF). FDA. October 2015 [2016-10-16]. （原始内容存档 (PDF)于2016-10-23）. For label updates see FDA index page for BLA 125518 （页面存档备份，存于互联网档案馆）
Amgen to Buy BioVex, Maker of Cancer Drugs. Bloomberg News via The New York Times. 2011-01-24 [2020-08-30]. （原始内容存档于2020-05-15）.
How does gene therapy work?. U.S. National Library of Medicine: Genetics Home Reference. [2019-12-05]. （原始内容存档于2019-12-05）（英语）.
How does gene therapy work?. U.S. National Library of Medicine: Genetics Home Reference. [2019-12-05]. （原始内容存档于2019-12-05）（英语）.
How does gene therapy work?. U.S. National Library of Medicine: Genetics Home Reference. [2019-12-05]. （原始内容存档于2019-12-05）（英语）.
Gene therapy - Mayo Clinic. www.mayoclinic.org. [2019-12-05]. （原始内容存档于2019-12-05）.
Services, U.S. Department of Health and Human. Vaccines.gov. www.vaccines.gov. [2020-08-30]. （原始内容存档于2017-07-29）（美国英语）.
Feasibility study for registration of medicine RIGVIR with the European Medicine Agency. European Commission. 2016-01-08 [2016-11-02]. （原始内容存档于2016-11-02）. However, further use and commercialisation in the EU is prevented as EU regulations require cancer medicines to be registered centrally through the European Medicine Agency (EMA). National registrations are not considered.
Rigvir cancer treatment at center of fresh controversy. [2020-08-30]. （原始内容存档于2019-03-27）.
Glybera: EPAR - Summary for the public (PDF). European Medicines Agency. [2019-11-25]. （原始内容存档 (PDF)于2020-07-20）.
Glybera: EPAR - Summary for the public (PDF). European Medicines Agency. [2019-11-25]. （原始内容存档 (PDF)于2020-07-20）.
FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. U.S. Food & Drug Administration. 2017-12-18 [2019-11-25]. （原始内容存档于2019-11-24）.
Package Insert - LUXTURNA (voretigene neparvovec-rzyl) (PDF). U.S. Food & Drug Administration. [2019-11-25]. （原始内容存档 (PDF)于2018-01-26）.
Luxturna : EPAR - Medicine overview (PDF). European Medicines Agency. [2019-11-25]. （原始内容存档 (PDF)于2019-08-31）.
Package Insert - ZOLGENSMA (PDF). U.S. Food & Drug Administration. [2019-11-25]. （原始内容存档于2019-11-19）.
Erman, Michael. Novartis says it knew of Zolgensma data problems before U.S. approval. Reuters. 2019-08-07 [2019-11-26]. （原始内容存档于2019-11-17）（英语）.
Erman, Michael. Novartis says it knew of Zolgensma data problems before U.S. approval. Reuters. 2019-08-07 [2019-11-26]. （原始内容存档于2019-11-17）（英语）.
Sepkowitz, Kent. West Nile Made Its U.S. Debut in the 1950s, in a Doctor's Syringe. The New York Times. 2009-08-24: D5 [2020-08-30]. （原始内容存档于2020-08-23）.

worldcat.org

Cross, Deanna; Burmester, James K. Gene Therapy for Cancer Treatment: Past, Present and Future. Clinical Medicine and Research. 2006, 4 (3): 218–227. ISSN 1539-4182. PMC 1570487 . PMID 16988102. doi:10.3121/cmr.4.3.218.
Bessis, N.; GarciaCozar, F. J.; Boissier, M.-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004, 11 (1): S10–S17. ISSN 1476-5462. PMID 15454952. doi:10.1038/sj.gt.3302364  （英语）.
Bessis, N.; GarciaCozar, F. J.; Boissier, M.-C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy. 2004, 11 (1): S10–S17. ISSN 1476-5462. PMID 15454952. doi:10.1038/sj.gt.3302364  （英语）.
Zhou, Ru; Caspi, Rachel R. Ocular immune privilege. F1000 Biology Reports. 2010-01-18, 2. ISSN 1757-594X. PMC 2948372 . PMID 20948803. doi:10.3410/B2-3.

zva.gov.lv

Latvijas Zāļu reģistrs. www.zva.gov.lv. [2017-12-17].